Legal Representation
Attorney
Muzamil Huq
USPTO Deadlines
Application History
34 eventsDate | Code | Type | Description |
---|---|---|---|
Jul 1, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
Mar 4, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Jan 4, 2025 | EX4G | S | SOU EXTENSION 4 GRANTED |
Jan 4, 2025 | EXT4 | S | SOU EXTENSION 4 FILED |
Jan 3, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
Jul 2, 2024 | EX3G | S | SOU EXTENSION 3 GRANTED |
Jul 2, 2024 | EXT3 | S | SOU EXTENSION 3 FILED |
Jul 2, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Jul 2, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
Jan 5, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Jan 3, 2024 | EX2G | S | SOU EXTENSION 2 GRANTED |
Jan 3, 2024 | EXT2 | S | SOU EXTENSION 2 FILED |
Jan 3, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
Dec 22, 2023 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
Dec 22, 2023 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
Dec 22, 2023 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
Jul 5, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Jul 3, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
Jul 3, 2023 | EX1G | S | SOU EXTENSION 1 GRANTED |
Jul 3, 2023 | EXT1 | S | SOU EXTENSION 1 FILED |
Jan 3, 2023 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
Nov 8, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION |
Nov 8, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
Oct 19, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
Oct 3, 2022 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
Sep 23, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
Sep 22, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
Sep 22, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
Mar 22, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN |
Mar 22, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
Mar 22, 2022 | GNRT | F | NON-FINAL ACTION E-MAILED |
Mar 16, 2022 | DOCK | D | ASSIGNED TO EXAMINER |
Sep 9, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
Jun 29, 2021 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 005
Pharmaceutical products, preparations, and substances for the prevention and treatment of cancer, infectious diseases, allergies, mental illnesses, chemotherapy side effects, radiation side effects, transplantation side effects, and viral, metabolic, cardiovascular, vascular, pulmonary, blood, dermatologic, fibrotic, autoimmune, inflammatory, neurodegenerative, neuromuscular, dietary deficiency, hereditary, endocrine, eye, ear, and voice related diseases and disorders; biological products, preparations, and substances being medical preparations for the prevention and treatment of cancer, infectious diseases, allergies, mental illnesses, chemotherapy side effects, radiation side effects, transplantation side effects, and viral, metabolic, cardiovascular, vascular, pulmonary, blood, dermatologic, fibrotic, autoimmune, inflammatory, neurodegenerative, neuromuscular, dietary deficiency, hereditary, endocrine, eye, ear, and voice related diseases and disorders; immunotherapies in the nature of medical preparations for the prevention and treatment of cancer, infectious diseases, allergies, mental illnesses, chemotherapy side effects, radiation side effects, transplantation side effects, and viral, metabolic, cardiovascular, vascular, pulmonary, blood, dermatologic, fibrotic, autoimmune, inflammatory, neurodegenerative, neuromuscular, dietary deficiency, hereditary, endocrine, eye, ear, and voice related diseases and disorders; vaccines; pharmaceuticals in the nature of biotechnology platform technology, namely, viral and vaccine vectors for delivery and insertion of function-altering genetic material into human and animal patients, plants, and crops, for visualization of specific cell types, for inducing humoral and cell-mediated responses, for targeting and killing cancer cells, for removing pathological functions, for controlling biological pests, and for boosting crop yields; chemical platform technology, namely, small molecule compounds being pharmaceuticals for inducing the expression of antioxidant, anti-inflammatory, and cytoprotective proteins in non-malignant tissues, for activating the immune system, for modulating blood flow in ischemic tissues, for upregulating proinflammatory mediators in tumors, and for treating plant diseases
Class 042
Scientific and medical research and development in the fields of pharmaceuticals, biologics, agriculture, pest control, biotechnology, immunotherapies, and vaccines
Additional Information
Pseudo Mark
EPICENT RX
Classification
International Classes
005
042
USPTO Documents
Click to view cached USPTO documents for this trademark
Only administrators can request new documents from USPTO